Tysabri Եվրոպական Միություն - իտալերեն - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - sclerosi multipla - immunosoppressori selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Parsabiv Եվրոպական Միություն - իտալերեն - EMA (European Medicines Agency)

parsabiv

amgen europe b.v. - etelcalcetide cloridrato - iperparatiroidismo, secondario - anti-parathyroid agents, calcium homeostasis - parsabiv è indicato per il trattamento dell'iperparatiroidismo secondario (shpt) in pazienti adulti con malattia renale cronica (ckd) in terapia emodialitica.